Current Oncology

Florida Cancer Specialists & Research Institute Best Practices Program Improves Treatment Response and Survival for Patients with Multiple Myeloma

Retrieved on: 
Thursday, January 25, 2024
Real-World Evidence, Death, Incidence, RN, BSN, Bachelor of Pharmacy, Partnership, Survival, RRMM, Multiple myeloma, CAPM, Bone marrow, Data, FDA, Current Oncology, FCS, Doctor of Philosophy, RPH, OCN, BP, Infrared spectroscopy correlation table, Immune system, Nursing

FORT MYERS, Fla., Jan. 25, 2024 /PRNewswire/ -- A best practices program developed at Florida Cancer Specialists & Research Institute (FCS) has been shown to improve outcomes for adult patients prescribed selinexor for the treatment of relapsed/refractory multiple myeloma (RRMM).

Key Points: 
  • A real-world study by FCS authors details a program to improve patient outcomes for multiple myeloma.
  • Results obtained from a one-year retrospective observational study using data collected by FCS' Real-World Evidence team were recently published in Current Oncology.
  • He added, "Our findings, as detailed in this article, support the hypothesis that a best practices program designed around specific anticancer drugs can optimize prescribing practices, leading to better disease control and improvements in a patient's cancer care journey."
  • The FCS Real-World Evidence team works with internal and external partners providing insights to improve treatment decisions and clinical outcomes based on evidence generated using real-world data.

As countries around the world accelerate their genome-based testing readiness, Canada's health systems can't afford to fall behind

Retrieved on: 
Wednesday, September 13, 2023
Lead, Reflex, University, Therapy, Current Oncology, Population health, Education, William Osler Health System, Public, NGS, Policy, Department of Medicine – University of Pamplona, Alert Ready, Cancer, GTA, Lung cancer, University of Ottawa, Oncology, Immunotherapy, Science, Public health, Patient, Division, Dalhousie University, School, Medicine, Diagnosis, WHO, Research, Health, Family, Metastasis, World Health Organization, Medical device, Nursing, Medical imaging

Alberta is followed by Quebec, British Columbia, Nova Scotia, and Ontario, ranked in order of their readiness grade.

Key Points: 
  • Alberta is followed by Quebec, British Columbia, Nova Scotia, and Ontario, ranked in order of their readiness grade.
  • "I feel like I'm living on borrowed time, and it has been tough on my family, knowing things could have been different.
  • Some of these tangible policy actions include:
    Developing province wide education and training standards to ensure consistency in the quality of testing service.
  • To make their health systems more resilient, countries around the globe are accelerating their progress on genome-based testing.

Montreal Oncology Medical Team Receives Award for Use of the Belong Beating Cancer Together App

Retrieved on: 
Monday, July 10, 2023
Oncology, English, Jewish General Hospital, Current Oncology, Riau rupiah, Patient, Prix, Clinical Medicine Insights: Oncology, Hope, General Hospital, Health, Nursing, Belong, Medicine

Belong provides Patient Support Programs (PSPs) for a wide variety of healthcare providers and systems globally.

Key Points: 
  • Belong provides Patient Support Programs (PSPs) for a wide variety of healthcare providers and systems globally.
  • The multidisciplinary oncology team guided hundreds of patients with the help of Belong's Beating Cancer Together app.
  • A recent study published by the CIUSSS West-Central Montreal's team in Current Oncology highlights the impact of Belong's app on patient care in their network.
  • "This award confirms our commitment and the excellence of our multidisciplinary oncology team toward patients and their families, which we were able to achieve using Belong's high-engagement platform."

Thermo Fisher Scientific Opens Oncomine Clinical Research Grant Call for Submissions and Announces Latest Awardees

Retrieved on: 
Monday, August 1, 2022
Biotechnology, Health, Other Health, Other Philanthropy, Philanthropy, Oncology, Other Science, Research, General Health, Hospitals, Fund Raising, Genetics, Science, Clinical Trials, NGS, PPD, Diversified Pharmaceutical Services, Thermo Fisher Scientific, Laboratory, Research, Liquid biopsy, Current Oncology, University, Patheon, Health, Mindful Scientific Inc., Cancer, Fisher Scientific, Applied Biosystems, Science, Patient, Precision medicine, Program, University of Western Australia, Investor, Plasma, Invitrogen, Fusion, William Osler Health System, Pharmaceutical industry, Medicine

As part of its continued commitment to expand the benefits of next-generation sequencing (NGS), Thermo Fisher Scientific is now accepting submissions for the fifth round of the Oncomine Clinical Research Grant program.

Key Points: 
  • As part of its continued commitment to expand the benefits of next-generation sequencing (NGS), Thermo Fisher Scientific is now accepting submissions for the fifth round of the Oncomine Clinical Research Grant program.
  • The program awards independent clinical research teams with financial support worth up to $200,000 in reagents and general funding.
  • Since its introduction in 2020, the Oncomine Clinical Research Grant program has provided support to more than 20 unique research projects across 11 countries in areas including hematology-oncology, immuno-oncology, liquid biopsy and gene fusion detection.
  • For more information on the Oncomine Clinical Research Grant Program and how to submit proposals, please visit www.oncomine.com/grants .

Pacylex Pharmaceuticals Announces Publication in Current Oncology of First Clinical Experience with an N-myristoyltransferase (NMT) inhibitor in a Patient with Diffuse Large B-cell Lymphoma (DLBCL)

Retrieved on: 
Monday, March 14, 2022
5-MeO-NMT, Survival, Program, Dasatinib, Wellcome Trust, University, Breast cancer, NMT2, Oral, Patient, Ibrutinib, AICE, Lymphoma, Relapse, NMT, School of Life Sciences (University of Dundee), Safety, Neoplasm, DLBCL, Family, B-cell lymphoma, Research, Cancer, Leukemia, Growth, Lung, Current Oncology, Alberta Innovates, Pharmaceutical industry, Telescopic sight

This Phase 1 study is primarily intended to determine the safety of PCLX-001 at escalating doses.

Key Points: 
  • This Phase 1 study is primarily intended to determine the safety of PCLX-001 at escalating doses.
  • Pacylex is developing PCLX-001 in the form of a once-a-day pill initially to treat leukemia and lymphoma.
  • Pacylex is a pharmaceutical company targeting hematologic and solid cancers with a new first-in-class therapeutic, headquartered in Edmonton, Alberta, Canada.
  • Pacylex initiated clinical studies in Canada in the fall of 2021 in diffuse large B-cell lymphoma and solid tumors.

Ayala Pharmaceuticals Announces Publication Highlighting Clinical Activity of its Gamma Secretase Inhibitor AL101 in Desmoid Tumors

Retrieved on: 
Thursday, September 23, 2021
People, T-Cell Acute Lymphoblastic Leukemia, Recurrence, ACC, Private Securities Litigation Reform Act, Quality, Growth, Safety, Aggressive fibromatosis, Adenoid cystic carcinoma, SEC, Confidentiality, T-ALL, PR, U.S. Securities and Exchange Commission, TNBC, Abdominal wall, Adult, Incidence, BMS, Organ dysfunction, PFS, Clinical trial, Current Oncology, Neoplasm, Annual report, Therapy, AYLA, NASDAQ, Plantar fibromatosis, FDA, Cancer, Multiple myeloma, ORR, MM, QOL, GLOBE, Chronic pain, MRI, Novartis, Risk, Doctor of Philosophy, Patient, Adolescence, Ownership, Head, Pivotal, COVID-19, DOR, Research, Quality of life, Pharmaceutical industry, Medical imaging

This publication highlights the potential of a gamma secretase inhibitor for the treatment of desmoid tumors.

Key Points: 
  • This publication highlights the potential of a gamma secretase inhibitor for the treatment of desmoid tumors.
  • The data included in the case study are based on earlier Phase 1 results and compassionate use of AL101 in desmoid tumors.
  • Both of these patients case studies represent additional evidence to support the development of our gamma secretase inhibitor, AL102 for the treatment of desmoid tumors.
  • The body of data conducted by BMS in patients with desmoid tumors implicating the role of gamma secretase inhibition furthers our hypothesis for treating desmoid tumors through AL102s mechanism of action, said Roni Mamluk, Ph.D., Chief Executive Officer of Ayala.